Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 9/20 | 0.55 |
| ▸ | ICAM1 | P05362 | 9/20 | 0.55 |
| ▸ | ITGAL | P20701 | 9/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CCKBR | P32239 | 1/20 | 0.48 |
| ▸ | ECE1 | P42892 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3500127 | 1.00 | ITGB2 (0.55) | ITGB2ICAM1ITGALMAPTHPGD | |
| SCHEMBL3497412 | 0.92 | MAPT (0.52) | ITGB2ICAM1ITGALMAPTHPGD | |
| SCHEMBL3497410 | 0.92 | MAPT (0.52) | ITGB2ICAM1ITGALMAPTHPGD | |
| Benzotript SCHEMBL93960 | 0.75 | ITGB2 (0.73) | ITGB2ICAM1ITGALCCKBR | |
| Benzotript SCHEMBL9818252 | 0.75 | ITGB2 (0.73) | ITGB2ICAM1ITGALCCKBR | |
| SCHEMBL3498867 | 0.73 | KMT2A (0.53) | MMP2MEN1KMT2A | |
| SCHEMBL3498868 | 0.73 | KMT2A (0.53) | MMP2MEN1KMT2A | |
| SCHEMBL28401652 | 0.73 | ALOX15 (0.69) | ITGB2ICAM1ITGALMAPTPOLB | |
| SCHEMBL28401650 | 0.73 | ALOX15 (0.69) | ITGB2ICAM1ITGALMAPTPOLB | |
| SCHEMBL3499323 | 0.73 | MCL1 (0.50) | POLBKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | ITGB2 2080/4885ICAM1 4138/4885ITGAL 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.